FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017725462> ?p ?o ?g. }

• W2017725462 endingPage "829" @default.
• W2017725462 startingPage "823" @default.
• W2017725462 abstract "The optimal therapy for primary mediastinal large B-cell lymphoma (PMLBCL) remains undefined. The superiority of intensive chemotherapy regimens (Methotrexate, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Bleomycin [MACOP-B]/Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Bleomycin [VACOP-B]) over Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP)-like chemotherapy is upheld by some authors. The role of radiotherapy is still debated. In the absence of randomized trials, we report clinical findings and treatment response in 53 consecutive patients treated with intensive chemotherapy and mediastinal involved-field radiation therapy (IFRT).Fifty-three consecutive patients with PMLBCL were retrospectively analyzed. Planned treatment consisted of induction chemotherapy (I-CT; Prednisone, Methotrexate, Doxorubicin, Cyclophosphamide, Etoposide-Mechloroethamine, Vincristine, Procarbazine, Prednisone [ProMACE-MOPP] in the first 2 patients, MACOP-B in the next 11, and VACOP-B in the last 40) followed by IFRT. Planned treatment was concluded in 43 of 53 patients; in 10 patients, I-CT was not immediately followed by IFRT. Among these 10 patients, 6 received high-dose chemotherapy (HD-CT) followed by IFRT, 2 received HD-CT, and 2 received no further treatment.After a median follow-up of 93.9 months (range, 6-195 months), 45 of 53 patients (84.9%) were alive without disease. Eight patients died: 7 of PMLBCL and 1 of toxicity during HD-CT. The 5-year disease-free survival (DFS) and overall survival rates were 93.42% and 86.6%, respectively. The response rates after I-CT were complete response (CR) in 20 (37.73%) and partial response (PR) in 30 (56.60%); 3 patients (5.66%) were considered nonresponders. Among patients in PR after chemotherapy, 92% obtained a CR after IFRT.Our report confirms the efficacy of intensive chemotherapy plus mediastinal IFRT. IFRT plays a pivotal role in inducing CR in patients in PR after chemotherapy." @default.
• W2017725462 created "2016-06-24" @default.
• W2017725462 creator A5013236194 @default.
• W2017725462 creator A5015917770 @default.
• W2017725462 creator A5026667247 @default.
• W2017725462 creator A5031591368 @default.
• W2017725462 creator A5049020305 @default.
• W2017725462 creator A5053589804 @default.
• W2017725462 creator A5057767492 @default.
• W2017725462 creator A5066814162 @default.
• W2017725462 creator A5086122997 @default.
• W2017725462 creator A5087672637 @default.
• W2017725462 date "2007-07-01" @default.
• W2017725462 modified "2023-10-18" @default.
• W2017725462 title "Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience" @default.
• W2017725462 cites W1874675686 @default.
• W2017725462 cites W1884420797 @default.
• W2017725462 cites W1914909684 @default.
• W2017725462 cites W1976635885 @default.
• W2017725462 cites W1988397560 @default.
• W2017725462 cites W2004723453 @default.
• W2017725462 cites W2029269328 @default.
• W2017725462 cites W2033063563 @default.
• W2017725462 cites W2047776379 @default.
• W2017725462 cites W2105114563 @default.
• W2017725462 cites W2106193652 @default.
• W2017725462 cites W2107202569 @default.
• W2017725462 cites W2115362683 @default.
• W2017725462 cites W2128627706 @default.
• W2017725462 cites W2129146771 @default.
• W2017725462 cites W2143483266 @default.
• W2017725462 cites W2168681651 @default.
• W2017725462 cites W2173169563 @default.
• W2017725462 cites W2204433245 @default.
• W2017725462 cites W2269250750 @default.
• W2017725462 cites W2313165570 @default.
• W2017725462 cites W2318772898 @default.
• W2017725462 cites W254931162 @default.
• W2017725462 cites W4205736005 @default.
• W2017725462 doi "https://doi.org/10.1016/j.ijrobp.2006.12.048" @default.
• W2017725462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17379431" @default.
• W2017725462 hasPublicationYear "2007" @default.
• W2017725462 type Work @default.
• W2017725462 sameAs 2017725462 @default.
• W2017725462 citedByCount "47" @default.
• W2017725462 countsByYear W20177254622012 @default.
• W2017725462 countsByYear W20177254622013 @default.
• W2017725462 countsByYear W20177254622014 @default.
• W2017725462 countsByYear W20177254622015 @default.
• W2017725462 countsByYear W20177254622016 @default.
• W2017725462 countsByYear W20177254622017 @default.
• W2017725462 countsByYear W20177254622018 @default.
• W2017725462 countsByYear W20177254622019 @default.
• W2017725462 countsByYear W20177254622021 @default.
• W2017725462 countsByYear W20177254622023 @default.
• W2017725462 crossrefType "journal-article" @default.
• W2017725462 hasAuthorship W2017725462A5013236194 @default.
• W2017725462 hasAuthorship W2017725462A5015917770 @default.
• W2017725462 hasAuthorship W2017725462A5026667247 @default.
• W2017725462 hasAuthorship W2017725462A5031591368 @default.
• W2017725462 hasAuthorship W2017725462A5049020305 @default.
• W2017725462 hasAuthorship W2017725462A5053589804 @default.
• W2017725462 hasAuthorship W2017725462A5057767492 @default.
• W2017725462 hasAuthorship W2017725462A5066814162 @default.
• W2017725462 hasAuthorship W2017725462A5086122997 @default.
• W2017725462 hasAuthorship W2017725462A5087672637 @default.
• W2017725462 hasConcept C126322002 @default.
• W2017725462 hasConcept C141071460 @default.
• W2017725462 hasConcept C143998085 @default.
• W2017725462 hasConcept C2776694085 @default.
• W2017725462 hasConcept C2776755627 @default.
• W2017725462 hasConcept C2778119113 @default.
• W2017725462 hasConcept C2778720950 @default.
• W2017725462 hasConcept C2779112685 @default.
• W2017725462 hasConcept C2779429289 @default.
• W2017725462 hasConcept C2779725641 @default.
• W2017725462 hasConcept C509974204 @default.
• W2017725462 hasConcept C71924100 @default.
• W2017725462 hasConcept C90924648 @default.
• W2017725462 hasConceptScore W2017725462C126322002 @default.
• W2017725462 hasConceptScore W2017725462C141071460 @default.
• W2017725462 hasConceptScore W2017725462C143998085 @default.
• W2017725462 hasConceptScore W2017725462C2776694085 @default.
• W2017725462 hasConceptScore W2017725462C2776755627 @default.
• W2017725462 hasConceptScore W2017725462C2778119113 @default.
• W2017725462 hasConceptScore W2017725462C2778720950 @default.
• W2017725462 hasConceptScore W2017725462C2779112685 @default.
• W2017725462 hasConceptScore W2017725462C2779429289 @default.
• W2017725462 hasConceptScore W2017725462C2779725641 @default.
• W2017725462 hasConceptScore W2017725462C509974204 @default.
• W2017725462 hasConceptScore W2017725462C71924100 @default.
• W2017725462 hasConceptScore W2017725462C90924648 @default.
• W2017725462 hasIssue "3" @default.
• W2017725462 hasLocation W20177254621 @default.
• W2017725462 hasLocation W20177254622 @default.
• W2017725462 hasOpenAccess W2017725462 @default.
• W2017725462 hasPrimaryLocation W20177254621 @default.
• W2017725462 hasRelatedWork W1516133847 @default.

• next